Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LBRX

LB Pharmaceuticals Inc

Feb 06 • 04:00PM ET

23.82

-0.04 -0.17 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF SCHA VTWO IWO IWN IWC SCHB RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	25.70%	Shs Outstand	25.30M	Perf Week	11.05%
Market Cap	602.62M	Forward P/E	-	EPS next Y	-	Insider Trans	332.91%	Shs Float	18.80M	Perf Month	13.48%
Enterprise Value	291.81M	PEG	-	EPS next Q	-0.45	Inst Own	77.65%	Short Float	9.53%	Perf Quarter	47.04%
Income	-	P/S	-	EPS this Y	-	Inst Trans	97.68%	Short Ratio	6.18	Perf Half Y	-
Sales	-	P/B	1.94	EPS next Y	-	ROA	-	Short Interest	1.79M	Perf YTD	7.01%
Book/sh	12.26	P/C	1.92	EPS next 5Y	-	ROE	-	52W High	24.95 -4.53%	Perf Year	-
Cash/sh	12.43	P/FCF	-	EPS past 3/5Y	-109.72% -	ROIC	-	52W Low	13.36 78.29%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.77% 9.18%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.91	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	47.60	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.37	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	47.60	EPS Q/Q	5.57%	SMA20	9.91%	Beta	-	Target Price	44.50
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	14.72%	Rel Volume	0.89	Prev Close	23.86
Employees	-	LT Debt/Eq	0.01	Earnings	Nov 06 BMO	SMA200	30.77%	Avg Volume	289.81K	Price	23.82
IPO	Sep 11, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-7.02% -	Trades		Volume	258,184	Change	-0.17%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-09-26	Initiated	Roth Capital	Buy
Oct-06-25	Initiated	Stifel	Buy	$27
Oct-06-25	Initiated	Piper Sandler	Overweight	$78
Oct-06-25	Initiated	Leerink Partners	Outperform	$34

Feb-05-26 08:00AM	LB Pharmaceuticals Announces $100.0 Million Private Placement (GlobeNewswire) +12.71%
Jan-27-26 08:06AM	LB Pharmaceuticals initiates Phase 2 trial of LB-102 (TipRanks)
Jan-26-26 08:00AM	LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program (GlobeNewswire) -6.40%
Jan-21-26 08:00AM	LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel (GlobeNewswire)
Jan-12-26 04:05PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
07:00AM	Loading…
Jan-06-26 07:00AM	LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture (GlobeNewswire)
Dec-10-25 05:04PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.29%
Dec-09-25 08:00AM	LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices (GlobeNewswire)
Nov-24-25 08:00AM	LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) +5.28%
Nov-12-25 04:15PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.63%
08:00AM	LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire)
Nov-06-25 04:05PM	LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference (GlobeNewswire)
08:12AM	LB Pharmaceuticals Inc.: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-14-25 08:30AM	LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs (GlobeNewswire)
08:30AM	Loading…
Oct-06-25 08:30AM	LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms (GlobeNewswire)
Sep-25-25 08:30AM	LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani (GlobeNewswire)
Sep-12-25 04:27PM	Crunching the numbers on this week's IPO performances (Yahoo Finance Video)

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Deep Track Biotechnology Maste	10% Owner	Sep 12 '25	Buy	15.00	2,000,000	30,000,000	2,686,138	Sep 16 06:09 PM
Deep Track Biotechnology Maste	10% Owner	Sep 12 '25	Buy	15.00	666,666	9,999,990	666,666	Sep 16 06:09 PM
Pontifax Management 4 G.P. (20	10% Owner	Sep 12 '25	Buy	15.00	1,000,000	15,000,000	1,411,681	Sep 16 04:15 PM
Nussbaum Ran	Director	Sep 12 '25	Buy	15.00	1,000,000	15,000,000	1,411,681	Sep 16 04:15 PM
Vida Ventures GP III, L.L.C.	10% Owner	Sep 12 '25	Buy	15.00	333,333	4,999,995	880,214	Sep 16 03:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LBRX

LB Pharmaceuticals Inc

Upgrade your FINVIZ experience